BN Business News
Add your company to Business Communicator →

Business · 26/02/2003Updated: 10/17/2026 · 1 min read

FDA Announces Opportunity for Hearing on Proposal to Revoke Delmont Laboratories' Biologics License

Summary

The FDA is seeking public input on a proposal to revoke Delmont Laboratories' biologics license for Polyvalent Bacterial Antigens due to concerns over the product's potency and potential safety risks.

Original source language: Federal Register — Food and Drug AdministrationOpen original release →

Explore insights

Business insights →